Published in World J Gastroenterol on November 14, 2015
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med (1993) 4.43
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Liver transplantation (2). N Engl J Med (1989) 2.93
Hepatitis B virus infection. Lancet (2014) 2.78
Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. Liver Transpl (2013) 2.15
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology (2011) 1.89
Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol (2006) 1.86
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther (2012) 1.81
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy. Liver Transpl (2001) 1.74
Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol (2004) 1.71
Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol (2012) 1.56
Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol (2014) 1.55
Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis (2007) 1.40
Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology (2009) 1.32
Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation (1998) 1.32
Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl (2004) 1.29
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl (2008) 1.27
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology (2008) 1.27
Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology (2014) 1.26
Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol (2010) 1.23
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology (2006) 1.10
The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat (2013) 1.10
Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl (2005) 1.10
Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation (1999) 1.09
Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut (2002) 0.99
Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol (2013) 0.99
Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis (2012) 0.98
The half-life of hepatitis B virions. Hepatology (2006) 0.98
Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl (2013) 0.97
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl (2013) 0.96
Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis. Clin Transplant (2011) 0.96
Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol (2013) 0.94
Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc (2010) 0.94
Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med (2015) 0.93
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
Management of patients with hepatitis B in special populations. World J Gastroenterol (2015) 0.93
Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl (2002) 0.93
Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int (2012) 0.92
Current management of hepatitis B virus infection before and after liver transplantation. Liver Int (2009) 0.92
The difficulties of managing severe hepatitis B virus reactivation. Liver Int (2011) 0.91
The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology (2000) 0.90
The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol (2012) 0.90
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol (2012) 0.90
Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol (2013) 0.90
Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg (2001) 0.89
Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation (2007) 0.89
Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant (2006) 0.88
Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl (2004) 0.88
New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int (2014) 0.88
Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut (1992) 0.87
De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol (2013) 0.86
Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci (2007) 0.86
De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir Ther (2011) 0.86
Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol (2014) 0.85
Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection. Hepatology (2015) 0.85
HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Int Rev Immunol (2014) 0.85
Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol (2011) 0.84
Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation (2013) 0.83
Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl (2012) 0.82
Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One (2014) 0.81
Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. Transplant Proc (2005) 0.81
Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Res (2013) 0.81
Current status of liver transplantation for hepatitis B virus. Clin Liver Dis (2011) 0.81
De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation. J Dig Dis (2013) 0.80
Antiviral treatment for hepatitis B virus recurrence following liver transplantation. Clin Transplant (2013) 0.80
Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B. World J Gastroenterol (2014) 0.80
The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant (2012) 0.80
Successful use of hepatitis B surface antigen-positive liver grafts - an effective source for donor organs in endemic areas: a single-center experience. Ann Transplant (2015) 0.80
Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol (2013) 0.80
Antimicrobial prophylaxis regimens following transplantation. Curr Opin Infect Dis (2011) 0.80
Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transplant Proc (2004) 0.79
Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol (2014) 0.79
4'-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology (2015) 0.78
Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience. Liver Transpl (2013) 0.78
Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis (2010) 0.78
Management of chronic hepatitis B in severe liver disease. World J Gastroenterol (2014) 0.78
Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2009) 0.78
Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol (2015) 0.77
Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation. Rev Esp Enferm Dig (2011) 0.77
Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis? Transpl Infect Dis (2015) 0.77
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. Drug Des Devel Ther (2015) 0.76
Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors. Liver Transpl (2012) 0.76
Analysis of S gene mutation of the hepatitis B virus in adult liver transplant recipients showing resistance to hepatitis B immunoglobulin therapy. Transplant Proc (2013) 0.76
Management of chronic hepatitis B infection. Arch Dis Child (2014) 0.76
Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Mon (2012) 0.76
Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation. Expert Opin Biol Ther (2015) 0.76
Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. World J Gastroenterol (2015) 0.76
Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation. World J Gastroenterol (2014) 0.76
Successful active immunization using a hepatitis B virus vaccination protocol for a recipient with hepatitis B core antibody-positive liver graft. Transplant Proc (2014) 0.75
Expanding the donor pool for liver transplant recipients using HBsAg positive grafts. J Hepatol (2014) 0.75